ライフサイエンスコーパス: allogeneic transplantation

1 tologous transplantation, and seven received allogeneic transplantation).

2 o exert veto functions and show evidence for allogeneic transplantation.

3 ates antitumor effects following MHC-matched allogeneic transplantation.

4 ceive similar conditioning regimens prior to allogeneic transplantation.

5 l immunity induces vascular accommodation in allogeneic transplantation.

6 ft-versus-tumour effect of reduced-intensity allogeneic transplantation.

7 tment and/or NK-mediated rejection following allogeneic transplantation.

8 ed as an alternative to bone marrow (BM) for allogeneic transplantation.

9 is novel agent is worthy of further study in allogeneic transplantation.

10 l for reconstitution of viral immunity after allogeneic transplantation.

11 erving graft-versus-lymphoma activity during allogeneic transplantation.

12 cells when used in preparative regimens for allogeneic transplantation.

13 preventing lung cellular infiltration after allogeneic transplantation.

14 omes of patients treated with autologous and allogeneic transplantation.

15 d with clinical outcomes after myeloablative allogeneic transplantation.

16 )-mobilized donors are increasingly used for allogeneic transplantation.

17 le fashion paralleling that for syngeneic or allogeneic transplantation.

18 obilize a high yield of progenitor cells for allogeneic transplantation.

19 h as alemtuzumab, systemic chemotherapy, and allogeneic transplantation.

20 spectively compared bone marrow and PBSC for allogeneic transplantation.

21 as a source of hematopoietic stem cells for allogeneic transplantation.

22 ucing tolerance in mice and monkey models of allogeneic transplantation.

23 ation of the role of conditioning therapy in allogeneic transplantation.

24 ne responses in a non-human primate model of allogeneic transplantation.

25 The only curative therapy is allogeneic transplantation.

26 8 effector subset elicited in vivo following allogeneic transplantation.

27 lantation, and with increasing frequency for allogeneic transplantation.

28 years from ASCT should be considered for an allogeneic transplantation.

29 successful strategies to use these cells for allogeneic transplantation.

30 prophylaxis to reduce early mortality after allogeneic transplantation.

31 es as well as the role of consolidation with allogeneic transplantation.

32 eing almost inevitable without consolidating allogeneic transplantation.

33 ted by 26.2%, in particular after relapse or allogeneic transplantation.

34 tients who reactivated cytomegalovirus after allogeneic transplantation.

35 portance of donor-recipient HLA matching for allogeneic transplantation.

36 lR, outcome was similar after autologous and allogeneic transplantation.

37 atification of children with AML and ALL for allogeneic transplantation.

38 of a telomere biology disorder who underwent allogeneic transplantation.

39 (GVHD) remains a significant complication of allogeneic transplantation.

40 a potential approach to immune modulation in allogeneic transplantation.

41 ents that may result in lower morbidity than allogeneic transplantation.

42 HHV-6 DNAemia was not so frequent after allogeneic transplantation.

43 ated, all exhibited WT1-CTL responses before allogeneic transplantation.

44 f hematopoietic stem cells (HSCs) for use in allogeneic transplantation.

45 e donor to proceed to a potentially curative allogeneic transplantation.

46 t/ABL1 was most prognostic for relapse after allogeneic transplantation.

47 ffectively with immunosuppressive therapy or allogeneic transplantation.

48 n of renal arteries after ischemia and after allogeneic transplantation.

49 tment and prevention of AML recurrence after allogeneic transplantation.

50 nonrelapse mortality after reduced intensity allogeneic transplantation.

51 dentify subjects most likely to benefit from allogeneic transplantation.

52 a promising novel immunomodulatory agent in allogeneic transplantation.

53 omorbidities should be considered for second allogeneic transplantation.

54 Encouraging results are reported after allogeneic transplantation.

55 d reduced-intensity conditioning followed by allogeneic transplantation.

56 versus-host disease (GVHD) prophylaxis after allogeneic transplantation.

57 Allogeneic transplantation (10-year probability, 7% vs 3

58 highly educated patients more often received allogeneic transplantation (16.3% v 8.7%).

59 chimerism could be detected without a prior allogeneic transplantation, (2) the toxicity of primary

60 ide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after dev

61 A second allogeneic transplantation after a prior allogeneic (all

62 nologically normal BALB/c mice that delaying allogeneic transplantation after TBI is a simple and eff

63 y Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known.

64 phoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-f

65 nts with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic

66 widely adopted as a source of stem cells for allogeneic transplantation, although controversy remains

67 Recent advances in allogeneic transplantation and autologous gene therapy s

68 on-free survival, and overall survival after allogeneic transplantation and conditioning with fludara

69 eripheral blood progenitor cells (PBPCs) for allogeneic transplantation and granulocytes for transfus

70 ion of peripheral blood progenitor cells for allogeneic transplantation and granulocytes for transfus

71 Nonmyeloablative allogeneic transplantation and high-dose radioimmunother

72 tions in patients as early as 3 months after allogeneic transplantation and may be an effective strat

73 Results were independent of allogeneic transplantation and similar in those age 70 t

74 cute leukemia survivors without a history of allogeneic transplantation and worst in patients with my

75 s costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs o

76 is of comparable intensity to that used for allogeneic transplantation, and offers an alternative ap

77 We compared treatment intensity, allogeneic transplantation, and response rates by educat

78 ched donors, the morbidities associated with allogeneic transplantation, and the prevalence of HIV-1

79 ve dose intensity, conditioning regimens for allogeneic transplantation are designed to immunosuppres

80 ersus-host disease following blood or marrow allogeneic transplantation are not yet available.

81 the pathways of innate immune activation in allogeneic transplantation are unclear.

82 isease and hematologists who are considering allogeneic transplantation as a curative treatment relat

83 ave supplanted bone marrow in autologous and allogeneic transplantation as a source of hematopoietic

84 econd remission (CR2) and then proceeding to allogeneic transplantation as the definitive curative ap

85 rafts devoid of immunologic complications of allogeneic transplantation, as well as generating nonhem

86 em autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous

87 nsplantation is an attractive alternative to allogeneic transplantation because of the intractable sh

88 molecules that have the potential to enhance allogeneic transplantation, boost blood cell production,

89 ated that the 4-day rest between the TBI and allogeneic transplantation broke the interaction of cell

90 exclusion criteria were similar to those for allogeneic transplantation but restricted to patients la

91 lymphocytes could greatly expand the role of allogeneic transplantation by reducing graft-versus-host

92 d, however, before the curative potential of allogeneic transplantation can be assessed.

93 Allogeneic transplantation can cure a number of hematolo

94 Allogeneic transplantation combined with immunosuppressi

95 important component of the cure mediated by allogeneic transplantation comes from a graft-versus-tum

96 CR) had a significantly better outcome after allogeneic transplantation compared with other consolida

97 d to add between $15,300 and $28,100 each to allogeneic transplantation costs.

98 Although allogeneic transplantation cures a small proportion of p

99 s the source of hematopoietic stem cells for allogeneic transplantation, currently the only curative

100 Early T-cell reconstitution following allogeneic transplantation depends on the persistence an

101 tion for patients who are not candidates for allogeneic transplantation due to the lack of an appropr

102 Allogeneic transplantation during remission offers the b

103 y establish the role of blood stem cells for allogeneic transplantation, especially in patients with

104 Differences in the antibody response to allogeneic transplantation exist between groups defined

105 nocompetent murine model of minor mismatched allogeneic transplantation followed by donor-derived CD1

106 tients who had undergone a reduced intensity allogeneic transplantation for acute myeloid leukemia we

107 set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphob

108 d FK506 can reduce the early mortality after allogeneic transplantation for advanced leukemia.

109 mission consolidation with cytarabine before allogeneic transplantation for AML in first CR is not as

110 haploidentical alphabeta+CD3+/CD19+-depleted allogeneic transplantation for children with nonmalignan

111 ansplant, is an important adverse outcome in allogeneic transplantation for CML.

112 improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignan

113 The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B

114 In conclusion, results of allogeneic transplantation for HS are encouraging, with

115 mortality was higher than 30%, such as with allogeneic transplantation for intermediate or advanced

116 All patients had undergone allogeneic transplantation for malignant or nonmalignant

117 KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM.

118 ively safe option compared with conventional allogeneic transplantation for patients who have failed

119 Case reports suggest that allogeneic transplantation for patients with HIV and hem

120 Allogeneic transplantation for patients with lymphoma wh

121 ance status, there are curative options with allogeneic transplantation for selected patients.

122 Matched related allogeneic transplantations for ALL in first complete re

123 arative regimen is an important component of allogeneic transplantations for myelodysplasia (MDS) or

124 e report the outcomes of patients undergoing allogeneic transplantations for myeloma and reported to

125 s that PBSCs are better than bone marrow for allogeneic transplantation from HLA-identical siblings i

126 ents heterozygous for FVLeiden who underwent allogeneic transplantation from homozygous FV wild-type

127 In the mouse model of corneal allogeneic transplantation, galectin-8-induced lymphangi

128 The role of allogeneic transplantation has also been redefined in li

129 y of graft-versus-host disease (GVHD) during allogeneic transplantation has recently been reported; h

130 Both autologous and allogeneic transplantation have been used to treat and c

131 For allogeneic transplantation, host rats received injection

132 e been identified in human skin cancer after allogeneic transplantation; however, the donor contribut

133 ction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibl

134 vanced phase CML would predict relapse after allogeneic transplantation in 176 independent CP CML cas

135 phalan and a purine analog was evaluated for allogeneic transplantation in 86 patients who had a vari

136 1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.

137 re treated differently, with some undergoing allogeneic transplantation in first remission.

138 In total, 228 (27%) patients received an allogeneic transplantation in first remission.

139 lity that T cell-mediated immune sequelae of allogeneic transplantation in humans may differ when don

140 TNF alone can substitute for allogeneic transplantation in inducing HCMV and MCMV ie

141 ult in toxicity when administered late after allogeneic transplantation in murine models of GVHD.

142 afts has been shown to ameliorate GVHD after allogeneic transplantation in murine models.

143 the safety and efficacy of nonmyeloablative allogeneic transplantation in patients with HIV infectio

144 zed nonrelapse-related mortality rates after allogeneic transplantation in patients with Hodgkin's ly

145 loablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplas

146 apted trials that evaluate reduced-intensity allogeneic transplantation in patients with predicted po

147 pite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lympho

148 poietic stem cells for patients that require allogeneic transplantation in the absence of readily ava

149 These results suggest that nonmyeloablative allogeneic transplantation in the context of highly acti

150 nd progenitor cells can be an alternative to allogeneic transplantation in the treatment of primary i

151 den the eligibility for potentially curative allogeneic transplantation in various disease categories

152 expanded the potential cellular sources for allogeneic transplantation, including matched unrelated

153 nsplantation, concurrent viral infection and allogeneic transplantation increased epithelial injury a

154 marrow (BM) cells can be transferred through allogeneic transplantation, influencing the recipient's

155 d induced pluripotent stem cells (iPSCs) for allogeneic transplantation is a major challenge in regen

156 Our data suggest that nonablative allogeneic transplantation is a safe and potentially eff

157 Determination of the optimal dose of TBI for allogeneic transplantation is complex and depends on sev

158 T-cell depletion of bone marrow for allogeneic transplantation is known to increase the risk

159 the regulation of the immune response after allogeneic transplantation is still poorly understood.

160 Allogeneic transplantation is typically limited to young

161 chronic myeloid leukemia (CML) on subsequent allogeneic transplantation is uncertain.

162 ngiogenesis occurred as early as day+2 after allogeneic transplantation mainly in GVHD typical target

163 (EGFP+) FCs persist for one month following allogeneic transplantation, making cold target inhibitio

164 Allogeneic transplantation may also be beneficial to a s

165 or (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of re

166 Use of allogeneic transplantation may result in cure as well, b

167 osis factor (TNF)-alpha, which is induced by allogeneic transplantation, may have a role in reactivat

168 For allogeneic transplantation, mobilized blood cell collect

169 cells, as a model of cord blood in a murine allogeneic transplantation model (C57BL/6 [H-2(b)] --> B

170 e effects of this peptide were studied in an allogeneic transplantation model involving vascularized

171 ukin (IL)-10 has proven effective in various allogeneic transplantation models and for preventing rec

172 arcoma cell lines and promotes metastasis in allogeneic transplantation models.

173 After allogeneic transplantation, murine stem cells (SCs) for

174 nd then used for islet autologous (n=21) and allogeneic transplantation (n=10).

175 Nonmyeloablative allogeneic transplantation (NMAT) infrequently cures act

176 Allogeneic transplantation of CCR5 null hematopoietic st

177 ive, organ, joint, and tissue function after allogeneic transplantation of children with mucopolysacc

178 Allogeneic transplantation of foreign organs or tissues

179 We report that allogeneic transplantation of genetically engineered (B2

180 tient was effectively cured of HIV following allogeneic transplantation of hematopoietic stem cells (

181 Allogeneic transplantation of hERG1-expressing cells int

182 Allogeneic transplantation of islets of Langerhans was f

183 n of ie gene expression in a murine model of allogeneic transplantation of kidneys latently infected

184 strate in mice that both congenic as well as allogeneic transplantation of low numbers of highly puri

185 Allogeneic transplantation of pancreatic islets for pati

186 The allogeneic transplantation of primordial germ cells (PGC

187 Allogeneic transplantation of radiation chimeras previou

188 For selected patients, both autologous and allogeneic transplantation offer the possibility of prol

189 term effects of low-dose irradiation used in allogeneic transplantation on stem cells is less well kn

190 ransplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide ma

191 New advances in allogeneic transplantation, particularly reduced-intensi

192 cally secondary AML, and treatment including allogeneic transplantation, patients with World Health O

193 n 65,000 transplant recipients, about 40% of allogeneic transplantations performed since 1964, and ab

194 lied a well-tolerated, nonirradiation-based, allogeneic transplantation protocol using nonmyeloablati

195 range, $28,200 to $148,200) and $105,300 for allogeneic transplantation (range, $32,500 to $338,000).

196 their induction and mechanism of function in allogeneic transplantation remain elusive.

197 dity and mortality rates, particularly after allogeneic transplantation, remain challenges that must

198 The relative merit of autologous versus allogeneic transplantation remains to be better defined.

199 mportant for the mediation and regulation of allogeneic transplantation responses.

200 Although allogeneic transplantation results in a lower risk of di

201 Though allogeneic transplantation results in long-term survival

202 pe CD4(+)NKT cells in suppressing GVHD in an allogeneic transplantation setting, demonstrating clinic

203 In the allogeneic transplantation setting, the one log more T c

204 aft-versus-leukemia effect, as occurs in the allogeneic transplantation setting.

205 e autologous and to approximately 75% in the allogeneic transplantation setting.

206 Nonmyeloablative allogeneic transplantation should be considered in high-

207 Allogeneic transplantation should only be performed in t

208 Rituximab treatment after allogeneic transplantation significantly reduced B-cell

209 Similarly in an allogeneic transplantation study (n = 335), diabetes was

210 In allogeneic transplantation, such adverse reactions can o

211 It is now well known that the outcome after allogeneic transplantation, such as incidence of acute r

212 gnificantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG.

213 Aside from allogeneic transplantation, the current standard of care

214 er, in mouse models of atheroma formation or allogeneic transplantation, the serological neutralizati

215 With regard to allogeneic transplantation, there is a growing realisati

216 mens, which have expanded the application of allogeneic transplantation to a growing number of hemato

217 m follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation

218 y of hematopoiesis, suggesting strategies in allogeneic transplantation to avoid the adverse effects

219 Exploring the potential of allogeneic transplantation to eradicate disease has ther

220 This benefit from GO2 was dependent on allogeneic transplantation to translate the better leuke

221 ce the antitumor effect, and, in the case of allogeneic transplantation, to reduce toxicity.

222 capsule before transplantation, could induce allogeneic transplantation tolerance across two-haplotyp

223 D) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathoge

224 s to decreasing the occurrence of GVHD after allogeneic transplantation use T-cell depletion, use imm

225 This study shows that allogeneic transplantation using CD34+ selected PBSC res

226 The curative potential of allogeneic transplantation using conventional myeloablat

227 reat patients whose conditions relapse after allogeneic transplantation using donor leukocyte infusio

228 stitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depleted mice as r

229 e biologic activity of donor immune cells in allogeneic transplantation varied between graft sources.

230 To clarify the indications for allogeneic transplantation vis-a-vis autologous transpla

231 continuous-infusion chemotherapy followed by allogeneic transplantation was 67 +/- 12% compared with

232 Allogeneic transplantation was allowed.

233 Allogeneic transplantation was associated with a signifi

234 alues after completion of treatment or after allogeneic transplantation was studied by using cause-sp

235 As T cells are activated in allogeneic transplantation, we determined the role of IL

236 relapse rates were observed when results of allogeneic transplantation were compared with syngeneic

237 Allogeneic transplantation with CD6 depleted bone marrow

238 Allogeneic transplantation with haemopoietic stem cells

239 first patient cured of HIV-1 infection after allogeneic transplantation with nonfunctional CCR5 corec

240 Reduction in the toxicity of allogeneic transplantation with nonmyeloablative inducti

241 The role of allogeneic transplantation with reduced-intensity condit

242 To review the outcomes of allogeneic transplantation with regimens of varying tota

243 We examined whether mixed allogeneic transplantation with syngeneic plus allogenei

244 uld potentially reduce disease relapse after allogeneic transplantation without increasing toxicity,

245 CML became the most frequent indication for allogeneic transplantation worldwide.